biostudies-literatureUnknown23(10)Mannarino LPleural mesothelioma (PM) is an aggressive tumor with few therapeutic options. Although patients with epithelioid PM (ePM) survive longer than non-epithelioid PM (non-ePM), heterogeneity of tumor response in ePM is observed. The role of the tumor immune microenvironment (TIME) in the development and progression of PM is currently considered a promising biomarker. A few studies have used high-throughput technologies correlated with TIME evaluation and morphologic and clinical data. This study aimed to identify different morphological, immunohistochemical, and transcriptional profiles that could potentially predict the outcome. A retrospective multicenter cohort of 129 chemonaive PM patients was recruited. Tissue slides were reviewed by dedicated pathologists for histotype classification andInternational journal of molecular sciences5786https://www.ebi.ac.uk/biostudies/studies/S-EPMC9144737biostudies-literatureEpithelioid Pleural Mesothelioma Is Characterized by Tertiary Lymphoid Structures in Long Survivors: Results from the MATCH Study.PMC9144737Moracci LVedovelli LInglesi APezzuto FCeresoli GLBosetti CLibener RAllavena PDe Simone IZucali PAAmodeo RPenpa SMarchini SOlteanu GECallari MDe Angelis ACalabrese FParacchini LDelfanti SMuzio AMannarino LLupi MD'Incalci MGrosso FfalseEpithelioid Pleural Mesothelioma Is Characterized by Tertiary Lymphoid Structures in Long Survivors: Results from the MATCH Study.Pleural mesothelioma (PM) is an aggressive tumor with few therapeutic options. Although patients with epithelioid PM (ePM) survive longer than non-epithelioid PM (non-ePM), heterogeneity of tumor response in ePM is observed. The role of the tumor immune microenvironment (TIME) in the development and progression of PM is currently considered a promising biomarker. A few studies have used high-throughput technologies correlated with TIME evaluation and morphologic and clinical data. This study aimed to identify different morphological, immunohistochemical, and transcriptional profiles that could potentially predict the outcome. A retrospective multicenter cohort of 129 chemonaive PM patients was recruited. Tissue slides were reviewed by dedicated pathologists for histotype classification and2022-01-01T00:00:00Z2022 May2025-04-05T11:59:05.177Z2024-11-05T20:39:53.338ZS-EPMC91447373562859710.3390/ijms23105786